Skip to main content
CLDX
NASDAQ Life Sciences

Celldex 提出公开股票发行方案以资助巴索利单抗的商业化

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
8
Price
$30.55
Mkt Cap
$2.081B
52W Low
$14.4
52W High
$34.52
Market data snapshot near publication time

summarizeSummary

Celldex Therapeutics宣布了一项拟议的承销公开发行普通股的计划，包括承销商购买额外股份的选择权。该公司计划利用净收益来资助正在进行的商业准备活动，以及潜在的巴索利单抗商业推出（如果获得批准），用于治疗慢性自发性荨麻疹（CSU），以及进一步的临床开发和一般公司用途。这一融资举措是在几天前报告的巴索利单抗的2期临床试验数据非常积极之后进行的。虽然这一举措在战略上旨在资助一款有前途的药物的商业化，但公开发行股票本质上会导致现有股东的股权被稀释，可能会对股票价格在短期内产生下行压力。交易者将密切关注发行的最终条款和规模，以评估其全部影响。

在该公告发布时，CLDX的交易价格为$30.55，交易所为NASDAQ，所属行业为Life Sciences，市值约为$20.8亿。 52周交易区间为$14.40至$34.52。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CLDX - Latest Insights

CLDX
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Celldex Seeks Shareholder Approval for 3.4M Share Increase in Equity Incentive Plan
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 06, 2026, 10:53 AM EDT
Source: GlobeNewswire
Importance Score:
7
Celldex Therapeutics Secures $345M from Public Offering, Underwriters Fully Exercise Option
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 5:14 PM EDT
Filing Type: 424B5
Importance Score:
8
Celldex Therapeutics Prices $300M Public Offering to Fund Barzolvolimab Commercialization and Pipeline
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Celldex Therapeutics Prices $300 Million Public Offering, Significant Dilution Expected
Sentiment: Negative
View Wiseek Article
CLDX
Apr 01, 2026, 9:48 PM EDT
Source: Reuters
Importance Score:
8
$300 Million Stock Offering Priced by Celldex at $29.00 Per Share
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 01, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex Proposes Public Stock Offering to Fund Barzolvolimab Commercialization
Sentiment: Negative
View Wiseek Article
CLDX
Mar 27, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex's Barzolvolimab Shows Profound, Durable Quality of Life Improvements in Phase 2 Urticaria Studies
Sentiment: Positive
View Wiseek Article
CLDX
Mar 01, 2026, 9:45 AM EST
Source: GlobeNewswire
Importance Score:
8
Barzolvolimab Retreatment Shows Profound Efficacy in Cold Urticaria and SD, Reinforcing Best-in-Class Profile
Sentiment: Positive
View Wiseek Article
CLDX
Feb 27, 2026, 2:45 PM EST
Source: GlobeNewswire
Importance Score:
9
Barzolvolimab Shows Sustained Efficacy, Disease Modification in Phase 2 Urticaria Data
Sentiment: Positive
View Wiseek Article
CLDX
Feb 25, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
Celldex Therapeutics Advances Multiple Clinical Programs, Secures Liquidity Through 2027
Sentiment: Positive
View Wiseek Article